Näytetään tulokset 1 - 10 / 252
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi
 Julkaisujen tiedon ikoni

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1126/science.adk0775
Klomp, Jeffrey A.; Klomp, Jennifer E.; Stalnecker, Clint A.; Bryant, Kirsten L.; Edwards, A. Cole; D...
Science2024 Julkaisujen tiedon ikoni

Atypical KRAS(G12R) Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

Vertaisarvioitu
Avoin saatavuus
DOI
10.1158/2159-8290.CD-19-1006
Hobbs, G. Aaron; Baker, Nicole M.; Miermont, Anne M.; Thurman, Ryan D.; Pierobon, Mariaelena; Tran, ...
Cancer Discovery2020 Julkaisujen tiedon ikoni

SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1097/PAI.0000000000000500
Felisiak-Golabek, Anna; Inaguma, Shingo; Kowalik, Artur; Wasag, Bartosz; Wang, Zeng-Feng; Zieba, Seb...
Applied immunohistochemistry and molecular morphology2018 Julkaisujen tiedon ikoni

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.celrep.2020.107764
Ozkan-Dagliyan, Irem; Diehl, J. Nathaniel; George, Samuel D.; Schaefer, Antje; Papke, Bjoern; Klotz-...
Cell Reports2020 Julkaisujen tiedon ikoni

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1038/s41467-024-52326-1
Lilja, Johanna; Kaivola, Jasmin; Conway, James R. W.; Vuorio, Joni; Parkkola, Hanna; Roivas, Pekka; ...
Nature communications2024 Julkaisujen tiedon ikoni

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Vertaisarvioitu
DOI
10.1126/scitranslmed.aaq1093
Kauko, Otto; O'Connor, Caitlin M.; Kulesskiy, Evgeny; Sangodkar, Jaya; Aakula, Anna; Izadmehr, Sudeh...
Science translational medicine2018 Julkaisujen tiedon ikoni

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras Mutant Lung Cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1158/1535-7163.MCT-18-0573
Talwelkar, Sarang S.; Nagaraj, Ashwini S.; Devlin, Jennifer R.; Hemmes, Annabrita; Potdar, Swapnil; ...
Molecular cancer therapeutics2019 Julkaisujen tiedon ikoni

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.ccell.2015.11.011
Hayes, Tikvah K.; Neel, Nicole F.; Hu, Chaoxin; Gautam, Prson; Chenard, Melissa; Long, Brian; Aziz, ...
Cancer cell2016 Julkaisujen tiedon ikoni

An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit <i>KRAS</i> Mutant Cancer Cell Growth

Vertaisarvioitu
Avoin saatavuus
DOI
10.1021/acs.jmedchem.3c02129
Kaya, Pelin; Schaffner-Reckinger, Elisabeth; Manoharan, Ganesh babu; Vukic, Vladimir; Kiriazis, Alex...
Journal of medicinal chemistry2024 Julkaisujen tiedon ikoni

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

Vertaisarvioitu
Avoin saatavuus
DOI
10.3389/fonc.2022.826073
Osterlund, Emerik; Ristimäki, Ari; Kytölä, Soili; Kuopio, Teijo; Heervä, Eetu; Muhonen, Timo; Halone...
Frontiers in oncology2022

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1126/science.adk0775
2024

Atypical KRAS(G12R) Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

Vertaisarvioitu
Avoin saatavuus
DOI
10.1158/2159-8290.CD-19-1006
2020

SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1097/PAI.0000000000000500
2018

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.celrep.2020.107764
2020

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1038/s41467-024-52326-1
2024

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Vertaisarvioitu
DOI
10.1126/scitranslmed.aaq1093
2018

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras Mutant Lung Cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1158/1535-7163.MCT-18-0573
2019

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.ccell.2015.11.011
2016

An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit <i>KRAS</i> Mutant Cancer Cell Growth

Vertaisarvioitu
Avoin saatavuus
DOI
10.1021/acs.jmedchem.3c02129
2024

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

Vertaisarvioitu
Avoin saatavuus
DOI
10.3389/fonc.2022.826073
2022